Is PT-141 (Bremelanotide) Legal in Louisiana?

What Is PT-141 (Bremelanotide) and Why Does Its Legal Status Matter?

PT-141 is the research name for bremelanotide, a synthetic melanocortin receptor agonist that acts on MC3R and MC4R receptors in the central nervous system to increase sexual desire. Unlike sildenafil or tadalafil, it does not work through vascular mechanisms. The FDA approved the finished drug product (Vyleesi, AMAG Pharmaceuticals) on June 21, 2019, specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1].

Because bremelanotide has an FDA-approved finished-drug counterpart, its legal status differs substantially from purely experimental peptides such as BPC-157 or TB-500. This distinction shapes every access pathway available to Louisiana patients.

The Difference Between the Research Peptide and the Approved Drug

Before FDA approval, "PT-141" circulated as a research chemical. Post-approval, the same molecule is a regulated prescription drug. Purchasing raw bremelanotide powder labeled "for research only" from an unverified vendor sits outside any legal patient-use framework and is not the same as obtaining a legitimate prescription. The FDA has issued warning letters to vendors marketing unapproved peptides in finished-dosage form [2].

Why State Law Matters Less Than Federal Law Here

Louisiana has no statute that independently bans or separately approves bremelanotide. The controlling framework is entirely federal: the Food, Drug, and Cosmetic Act (FD&C Act), FDA labeling requirements, and DEA scheduling. Louisiana law then layers on top through the Louisiana Medical Practice Act (La. R.S. 37:1261 et seq.) and the Louisiana Board of Pharmacy's compounding regulations, which align with federal USP standards.

Federal Legal Framework for Bremelanotide

FDA Approval and Prescribing Boundaries

The FDA granted approval to Vyleesi on June 21, 2019, based on two Phase 3 randomized controlled trials (RECONNECT studies, combined N=1,247) showing statistically significant improvements in desire and distress scores versus placebo [3]. The prescribing information specifies premenopausal women with acquired, generalized HSDD as the approved population [1].

Prescribing bremelanotide off-label, for example to men with erectile dysfunction or to postmenopausal women, is not prohibited by federal law. The FDA's longstanding policy, documented in its guidance on off-label use, permits licensed physicians to prescribe approved drugs beyond the labeled indication based on sound medical judgment [4]. A 2014 randomized trial published in the Journal of Sexual Medicine (N=394) demonstrated statistically significant improvements in erectile function scores with bremelanotide versus placebo, supporting the evidence base for male off-label use, though this indication remains unapproved [5].

DEA Scheduling

Bremelanotide is not listed in any DEA schedule under the Controlled Substances Act [6]. This means no DEA prescribing number is required specifically for this drug, and no federal quantity limits tied to controlled-substance rules apply. Standard prescription documentation requirements under Louisiana state law still govern the transaction.

The FDA's "Bulks List" and Compounding Pharmacies

This is where the legal picture for compounded PT-141 gets specific. Under Section 503A of the FD&C Act, a state-licensed pharmacy may compound a drug for an individual patient with a valid prescription if the drug is not essentially a copy of a commercially available product and meets USP standards [7]. Because Vyleesi (bremelanotide 1.75 mg auto-injector) is commercially available, a 503A pharmacy compounding the same dose in the same route may face "essentially a copy" scrutiny.

However, compounding pharmacies have produced bremelanotide in formulations that differ from Vyleesi. Variations include different concentrations, multi-dose vials, or combined formulations. These can qualify under 503A if a prescriber documents clinical rationale for the non-standard formulation. A 503B outsourcing facility may not compound a drug that is on the FDA-approved list without meeting additional criteria under Section 503B of the FD&C Act [8].

The practical takeaway: a Louisiana prescriber can write for a non-commercially-equivalent compounded bremelanotide formulation, and a 503A-registered pharmacy can legally fill it, provided the compounding pharmacy meets USP 795 sterile-compounding standards (or USP 797 for injectable preparations) and the prescription is patient-specific.

Louisiana-Specific Rules and Access Pathways

Louisiana Medical Practice Act and Prescribing Authority

Under Louisiana Revised Statutes 37:1261 through 37:1290, a licensed physician, advanced practice registered nurse (APRN) with prescriptive authority, or physician assistant with a supervising agreement may prescribe bremelanotide [9]. A valid prescriber-patient relationship must exist. Louisiana law does not require an in-person visit to establish this relationship for most medications; the Louisiana Telehealth Access Act (La. R.S. 40:1223.3) explicitly permits telehealth prescribing when the prescriber conducts a clinical evaluation adequate to diagnose and treat the condition [10].

This means a Louisiana resident can complete an intake evaluation with a licensed Louisiana prescriber via synchronous video, receive a bremelanotide prescription electronically, and have it filled at a licensed pharmacy.

Louisiana Board of Pharmacy and Compounding Standards

The Louisiana Board of Pharmacy (LABP) requires that compounding pharmacies in-state comply with USP Chapter 797 for sterile preparations such as injectable bremelanotide [11]. Out-of-state pharmacies shipping compounded bremelanotide into Louisiana must be licensed as non-resident pharmacies with the LABP and must comply with both their home-state standards and Louisiana's non-resident pharmacy requirements.

Who Qualifies for a Bremelanotide Prescription in Louisiana?

The FDA-approved indication covers premenopausal women with acquired, generalized HSDD. For that population, a prescriber evaluates whether the disorder is not caused by a co-existing medical or psychiatric condition, relationship distress, or medication side effects, consistent with the DSM-5 diagnostic criteria for FSIAD (Female Sexual Interest/Arousal Disorder) [12].

Off-label candidates include:

• Premenopausal women who did not respond to flibanserin (Addyi)
• Postmenopausal women whose prescriber documents clinical rationale
• Men with psychogenic or mixed erectile dysfunction where PDE5 inhibitors are contraindicated or insufficient

A prescriber's documentation of clinical rationale protects both the patient and the provider under Louisiana's medical practice act.

How to Get PT-141 (Bremelanotide) in Louisiana: Step-by-Step

Step 1. Schedule a Clinical Evaluation

Contact a Louisiana-licensed prescriber with experience in sexual medicine, endocrinology, or women's health. Telehealth platforms licensed in Louisiana, including HealthRX, offer synchronous video consultations. The evaluation should include a detailed sexual history, review of concurrent medications, and assessment of cardiovascular risk (bremelanotide transiently increases blood pressure by an average of 2 mmHg systolic and 1 mmHg diastolic for approximately 12 hours post-dose, per the Vyleesi prescribing information) [1].

Patients with uncontrolled hypertension or known cardiovascular disease are not good candidates. The FDA prescribing information for Vyleesi carries a warning for this reason [1].

Step 2. Obtain a Prescription

If the prescriber determines bremelanotide is appropriate, they issue a written or electronic prescription. For the FDA-approved Vyleesi product, the prescription can be filled at any Louisiana retail pharmacy that stocks it. For a compounded formulation, the prescription specifies the exact compound, concentration, quantity, and clinical rationale.

Step 3. Select a Pharmacy

Options for Louisiana patients include:

• Retail pharmacy (Vyleesi brand): Major chains (CVS, Walgreens, Walmart) can order Vyleesi. Cost without insurance runs approximately $800 to $1,000 per carton (four auto-injectors); manufacturer savings programs may reduce out-of-pocket costs significantly.
• 503A compounding pharmacy: A licensed Louisiana compounding pharmacy or a LABP-registered non-resident compounding pharmacy. Compounded bremelanotide typically costs $150 to $350 per vial depending on concentration and volume, though pricing varies by pharmacy.
• 503B outsourcing facility: Limited applicability for individual prescriptions; primarily for institutional use.

Step 4. Administration and Follow-Up

Bremelanotide is injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The prescribing information instructs patients not to use more than one dose within 24 hours and no more than approximately 8 doses per month [1]. Follow-up with the prescriber at 4 to 8 weeks allows assessment of response and side effects, including nausea (the most common adverse event, occurring in approximately 40% of patients in the RECONNECT trials) [3].

Safety Profile and Contraindications

Common Adverse Events

In the pooled RECONNECT Phase 3 data (N=1,247), nausea occurred in 40.0% of bremelanotide-treated patients versus 1.3% placebo, flushing in 20.4% versus 0%, and headache in 11.3% versus 2.6% [3]. Most nausea was transient and resolved without treatment, though approximately 13% of patients used an antiemetic. Prescribers in Louisiana frequently co-prescribe ondansetron 4 mg to be taken 30 minutes before bremelanotide to reduce nausea burden.

Blood Pressure and Cardiovascular Risk

The transient blood-pressure elevation (average peak increase of 6 mmHg systolic, returning to baseline within 12 hours) is the primary cardiovascular concern [1]. The FDA prescribing information advises against use in patients with known cardiovascular disease. Louisiana prescribers should review baseline blood pressure at the time of evaluation.

Hyperpigmentation

Focal hyperpigmentation of the face, breasts, or gums has been reported with repeated bremelanotide use. The RECONNECT trials noted this adverse event in approximately 1% of participants but emphasized it may be persistent. Patients with darker skin tones or predisposition to melasma warrant specific counseling [3].

Drug Interactions

Bremelanotide slows gastric emptying, which may reduce the rate of absorption of orally administered drugs. The prescribing information specifically flags indomethacin, naltrexone, and drugs requiring specific absorption timing as having the potential for interaction [1]. Louisiana prescribers managing patients on chronic oral medications should review this list carefully.

Off-Label Use in Men: What the Evidence Shows

The FDA did not approve bremelanotide for any male indication. Evidence still exists. A Phase 2b randomized, double-blind, placebo-controlled trial published in the Journal of Sexual Medicine (N=394 men with erectile dysfunction) found that bremelanotide 1.75 mg subcutaneous produced a statistically significant improvement in the IIEF erectile function domain score compared to placebo (mean difference 2.7 points, P<0.01) [5]. A smaller Phase 2 study (N=168) showed benefit in men who had previously failed sildenafil [13].

The Endocrine Society's 2016 clinical practice guideline on male hypogonadism does not address bremelanotide directly but notes that central mechanisms of sexual desire are distinct from peripheral vascular mechanisms, leaving room for central-acting agents in refractory cases [14].

Off-label prescribing for men in Louisiana follows the same legal path described above: a licensed prescriber documents clinical rationale, and a licensed pharmacy fills the prescription. No additional state-level approval is needed.

What Is Not Legal: Purchasing Without a Prescription

Several online vendors sell "research-grade" bremelanotide powder or pre-mixed solutions labeled "not for human use." This pathway is not legally equivalent to a prescription. Under the FD&C Act, selling a drug intended for human use without an approved new drug application or valid compounding exemption violates federal law regardless of the label language [15]. The FDA has taken enforcement action against peptide vendors selling unapproved finished-dosage peptide products [2].

Louisiana residents purchasing from such vendors receive a product with no verified potency, sterility, or purity, and no prescriber oversight. This is a distinct legal and clinical risk, separate from obtaining bremelanotide through a licensed prescriber and pharmacy.

Telehealth Access to PT-141 in Louisiana

Louisiana's Telehealth Access Act permits synchronous audio-video consultations to establish a prescriber-patient relationship for the purpose of prescribing. The state does not require a prior in-person visit for most non-controlled substances, and bremelanotide is not a controlled substance [10]. This opens a practical access pathway for Louisiana residents in rural parishes where sexual-medicine specialists are sparse.

Prescribers using telehealth to prescribe bremelanotide must be licensed in Louisiana. Out-of-state prescribers without Louisiana licensure may not prescribe to Louisiana patients via telehealth unless they hold a Louisiana telemedicine license or qualify under a specific interstate compact.

HealthRX operates with Louisiana-licensed providers and can complete the evaluation, prescribe, and coordinate with a LABP-compliant pharmacy in a single care pathway.

Summary of the Legal Framework at a Glance

The table below maps each access scenario to its legal status under federal and Louisiana law.

| Access Scenario | Federal Status | Louisiana Status | |---|---|---| | Vyleesi (brand) with valid Rx | Legal | Legal | | Compounded bremelanotide (503A, non-copy formulation) with valid Rx | Legal with conditions | Legal with conditions | | Compounded bremelanotide (503B outsourcing) | Legal for institutional use | Legal for institutional use | | Off-label prescribing (men, postmenopausal women) | Legal (off-label) | Legal (off-label) | | Research-chemical vendor, no Rx | Violates FD&C Act | No separate state exemption | | Telehealth prescription from Louisiana-licensed provider | Legal | Legal under La. R.S. 40:1223.3 |